» Articles » PMID: 32725439

A Cross-cultural Perspective on Intrathecal Opioid Therapy Between German and Iranian Patients

Overview
Specialty Social Sciences
Date 2020 Jul 30
PMID 32725439
Authors
Affiliations
Soon will be listed here.
Abstract

Patients often adhere to intrathecal opioid therapy (IOT) for many years, despite the lack of scientific evidence for its efficacy and the scarce knowledge about long-term effects. Moreover, there is no knowledge on how the efficacy of IOT is influenced by cultural factors. We assessed the long-term efficacy and frequency of side effects of IOT in two culturally different patient samples. A chart review was conducted of all patients with IOT, who had been treated in interdisciplinary pain centers in Freiburg and in Tehran in a 15-year span. Personal data, diagnosis, duration of pain disease, pump type in use, revision operations, and opioid doses were recorded. Patients completed a questionnaire containing pain scores, pain-related disability (PDI), anxiety, depression, and unwanted side effects. Fourteen Iranian and 36 German patients (32 m/18 f) were studied. Mean duration of IOT was 10.2 years. Pain levels prior to IOT were 7.64 (NRS) (range 4-10, SD 1.64), 3.86 (range 0-9, SD 2.32) directly after pump implantation, and 4.17 (range 0-10, SD 2.11) at time of follow-up. Iranian patients had significantly lower pain levels directly after implantation, depression scores, and pain-related disability. Frequent side effects were obstipation, sexual dysfunction, urinary retention, and fatigue. Most side effects were significantly less frequent in the Iranian sample. There were no severe complications or permanent neurological deficit. Our study demonstrates the effectiveness of IOT also for long-term application. Differences in clinical efficacy are partially due to cultural factors. Side effects are frequent but not limiting patient satisfaction.

Citing Articles

Evaluation of long-term outcomes with intrathecal opioid treatment: a comparison utilizing data derived from pain clinic populations in Australia and New Zealand.

Comber E, Strong J, Moore O, Khan A, OCallaghan J, Manion B Front Pain Res (Lausanne). 2025; 6:1527371.

PMID: 40026615 PMC: 11868084. DOI: 10.3389/fpain.2025.1527371.

References
1.
Turner E, Matthews A, Linardatos E, Tell R, Rosenthal R . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358(3):252-60. DOI: 10.1056/NEJMsa065779. View

2.
Adelmanesh F, Arvantaj A, Rashki H, Ketabchi S, Montazeri A, Raissi G . Results from the translation and adaptation of the Iranian Short-Form McGill Pain Questionnaire (I-SF-MPQ): preliminary evidence of its reliability, construct validity and sensitivity in an Iranian pain population. Sports Med Arthrosc Rehabil Ther Technol. 2011; 3(1):27. PMC: 3225325. DOI: 10.1186/1758-2555-3-27. View

3.
Hassenbusch S, Portenoy R, Cousins M, Buchser E, Deer T, Du Pen S . Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-- report of an expert panel. J Pain Symptom Manage. 2004; 27(6):540-63. DOI: 10.1016/j.jpainsymman.2004.03.001. View

4.
Levy R . The failed and future promise of intraspinal drug administration for neurologic disorders. Neuromodulation. 2012; 15(3):165-70. DOI: 10.1111/j.1525-1403.2012.00468.x. View

5.
Bromet E, Andrade L, Hwang I, Sampson N, Alonso J, de Girolamo G . Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011; 9:90. PMC: 3163615. DOI: 10.1186/1741-7015-9-90. View